Amylin Said to Draw First-Round Bids From Sanofi, Merck

Amylin Pharmaceuticals Inc., the diabetes drugmaker that has put itself up for sale, received offers from Sanofi (SAN) and Merck & Co. in an initial round of bidding, said three people familiar with the process.

The companies made bids of at least $25 a share, said the people, who declined to be identified as the deliberations are private. That would value Amylin at more than $4 billion, based on its shares outstanding as of April 26. Offers were due yesterday for the San Diego-based company, whose medicines include Bydureon and Byetta, the people said.

Takeda Pharmaceutical Co. and Bristol-Myers Squibb Co. (BMY) indicated to Amylin they also would make bids, the people said. Amylin began looking for suitors with Credit Suisse Group AG and Goldman Sachs Group Inc. after rejecting a $3.5 billion offer from Bristol-Myers this year, people with knowledge of the matter said last month.

“Diabetes is one of the last few monolithic market opportunities,” Michael King, an analyst with Rodman & Renshaw in New York, said in a telephone interview. “All you have to do is look at the statistics. The numbers are enormous and growing.”

Pfizer Inc. (PFE), AstraZeneca Plc (AZN) and Roche Holding AG (ROG) had signed confidentiality agreements on Amylin’s sale process, people familiar with the matter said this month. It wasn’t clear whether they decided to move ahead with bids.

Spokesmen at Sanofi, Roche and AstraZeneca declined to comment. Representatives at Merck, Amylin, Pfizer and Bristol-Myers declined to comment. A U.S.-based spokeswoman for Takeda declined to comment.

Amylin rose 8.4 percent to $27.96 at the close yesterday in New York, the biggest single-day gain in a month.

Bydureon Approval

Amylin received approval in January for Bydureon, a once-weekly formulation of its earlier medicine Byetta, and the drugs may draw $1.5 billion in annual revenue in the next few years, said Phil Nadeau, an analyst with Cowen & Co. in New York.

“For most of these companies, Amylin would be complementary to what they have,” Nadeau said. “Each of these has a diabetes franchise and sales force and has been successful to some extent in the past. They could presumably make Bydureon a bigger product than Amylin is making it.”

Amylin’s revenue topped $650 million last year and is poised to increase about 5 percent in 2012, according to analyst estimates compiled by Bloomberg. About 346 million people in the world have diabetes, and the number of deaths from the chronic disease may double from 2005 to 2030, according to the World Health Organization. Drugmakers are working to introduce new therapies to the market, with mixed results.

Sanofi’s Drugs

Sanofi, based in Paris, is developing its diabetes business and working on lixisenatide, a treatment belonging to the same drug class as Byetta and Bydureon. Roche, based in Basel, Switzerland, returned rights to a similar experimental medicine, known as taspoglutide, to developer Ipsen SA last year after patients dropped out of trials because of side effects.

Bristol-Myers, based in New York, and London-based AstraZeneca failed to win U.S. clearance this year to sell the experimental diabetes treatment dapagliflozin as regulators sought more safety data.

Merck, in Whitehouse Station, New Jersey, sells the diabetes drugs Januvia and Janumet, which drew $919 million and $392 million in first-quarter revenue, respectively. Purchasing Amylin would make sense for the drugmaker because “they’ve got a robust diabetes franchise already,” King said.

Amylin had been seeking a partner to help market Bydureon outside the U.S. since November, when it ended a collaboration with Eli Lilly & Co. The company rejected Bristol-Myers’s $22-a-share bid in February, said people familiar with the matter.

To contact the reporters on this story: Jeffrey McCracken in New York at jmccracken3@bloomberg.net; Jacqueline Simmons in Paris at jackiem@bloomberg.net; Albertina Torsoli in Paris at atorsoli@bloomberg.net

To contact the editors responsible for this story: Jacqueline Simmons at jackiem@bloomberg.net; Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.